DEXCOM INC (DC4.DE) Stock Fundamental Analysis
Europe - FRA:DC4 - US2521311074 - Common Stock
61.47 EUR
+2.27 (+3.83%)
We assign a fundamental rating of 6 out of 10 to DC4. DC4 was compared to 59 industry peers in the Health Care Equipment & Supplies industry. DC4 scores excellent on profitability, but there are some minor concerns on its financial health. DC4 is valued quite expensively, but it does show have an excellent growth rating. With these ratings, DC4 could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year DC4 was profitable.
DC4 had a positive operating cash flow in the past year.
Each year in the past 5 years DC4 has been profitable.
In the past 5 years DC4 always reported a positive cash flow from operatings.
1.2 Ratios
DC4 has a better Return On Assets (7.80%) than 79.66% of its industry peers.
The Return On Equity of DC4 (22.21%) is better than 91.53% of its industry peers.
DC4's Return On Invested Capital of 14.52% is amongst the best of the industry. DC4 outperforms 94.92% of its industry peers.
DC4 had an Average Return On Invested Capital over the past 3 years of 11.25%. This is above the industry average of 9.04%.
The 3 year average ROIC (11.25%) for DC4 is below the current ROIC(14.52%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| ROIC | 14.52% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
DC4 has a better Profit Margin (13.29%) than 76.27% of its industry peers.
DC4's Profit Margin has improved in the last couple of years.
DC4 has a Operating Margin of 17.22%. This is in the better half of the industry: DC4 outperforms 76.27% of its industry peers.
DC4's Operating Margin has improved in the last couple of years.
The Gross Margin of DC4 (60.01%) is comparable to the rest of the industry.
DC4's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.22% | ||
| PM (TTM) | 13.29% | ||
| GM | 60.01% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DC4 is creating value.
The number of shares outstanding for DC4 has been increased compared to 1 year ago.
Compared to 5 years ago, DC4 has more shares outstanding
The debt/assets ratio for DC4 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.96 indicates that DC4 is not in any danger for bankruptcy at the moment.
DC4 has a better Altman-Z score (4.96) than 83.05% of its industry peers.
DC4 has a debt to FCF ratio of 4.38. This is a neutral value as DC4 would need 4.38 years to pay back of all of its debts.
DC4 has a Debt to FCF ratio of 4.38. This is in the better half of the industry: DC4 outperforms 61.02% of its industry peers.
DC4 has a Debt/Equity ratio of 0.50. This is a neutral value indicating DC4 is somewhat dependend on debt financing.
The Debt to Equity ratio of DC4 (0.50) is worse than 61.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.38 | ||
| Altman-Z | 4.96 |
ROIC/WACC1.85
WACC7.84%
2.3 Liquidity
A Current Ratio of 1.52 indicates that DC4 should not have too much problems paying its short term obligations.
The Current ratio of DC4 (1.52) is comparable to the rest of the industry.
DC4 has a Quick Ratio of 1.35. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
DC4 has a Quick ratio of 1.35. This is in the better half of the industry: DC4 outperforms 66.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The earnings per share for DC4 have decreased by -2.86% in the last year.
Measured over the past years, DC4 shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.25% on average per year.
The Revenue has grown by 9.30% in the past year. This is quite good.
The Revenue has been growing by 22.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
3.2 Future
The Earnings Per Share is expected to grow by 22.60% on average over the next years. This is a very strong growth
Based on estimates for the next years, DC4 will show a quite strong growth in Revenue. The Revenue will grow by 13.90% on average per year.
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
DC4 is valuated quite expensively with a Price/Earnings ratio of 42.10.
DC4's Price/Earnings ratio is in line with the industry average.
DC4's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.57.
With a Price/Forward Earnings ratio of 27.15, DC4 can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as DC4.
The average S&P500 Price/Forward Earnings ratio is at 23.09. DC4 is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.1 | ||
| Fwd PE | 27.15 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DC4 is valued a bit more expensive than the industry average as 61.02% of the companies are valued more cheaply.
DC4's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.02 | ||
| EV/EBITDA | 25.34 |
4.3 Compensation for Growth
DC4's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of DC4 may justify a higher PE ratio.
DC4's earnings are expected to grow with 24.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.57
PEG (5Y)1.44
EPS Next 2Y26.2%
EPS Next 3Y24.65%
5. Dividend
5.1 Amount
DC4 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:DC4 (10/22/2025, 7:00:00 PM)
61.47
+2.27 (+3.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap24.11B
Revenue(TTM)4.30B
Net Income(TTM)571.50M
Analysts84.57
Price Target89.5 (45.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.34%
Min EPS beat(2)-4.09%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-1.87%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)9.43%
EPS beat(12)10
Avg EPS beat(12)14.38%
EPS beat(16)11
Avg EPS beat(16)8.49%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-1.66%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-0.42%
PT rev (1m)0%
PT rev (3m)0.76%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)0.28%
EPS NY rev (1m)0.14%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.1 | ||
| Fwd PE | 27.15 | ||
| P/S | 6.51 | ||
| P/FCF | 49.02 | ||
| P/OCF | 28.33 | ||
| P/B | 10.87 | ||
| P/tB | 11.37 | ||
| EV/EBITDA | 25.34 |
EPS(TTM)1.46
EY2.38%
EPS(NY)2.26
Fwd EY3.68%
FCF(TTM)1.25
FCFY2.04%
OCF(TTM)2.17
OCFY3.53%
SpS9.45
BVpS5.65
TBVpS5.41
PEG (NY)1.57
PEG (5Y)1.44
Graham Number13.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| ROCE | 18.43% | ||
| ROIC | 14.52% | ||
| ROICexc | 53.56% | ||
| ROICexgc | 59.66% | ||
| OM | 17.22% | ||
| PM (TTM) | 13.29% | ||
| GM | 60.01% | ||
| FCFM | 13.27% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.38 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 176.58% | ||
| Cap/Sales | 9.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.12% | ||
| Profit Quality | 99.88% | ||
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 4.96 |
F-Score6
WACC7.84%
ROIC/WACC1.85
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%
EBIT growth 1Y6.1%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year77.25%
EBIT Next 3Y38.83%
EBIT Next 5Y31.4%
FCF growth 1Y22.49%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y28.04%
OCF growth 3Y30.77%
OCF growth 5Y25.76%